Data Presented at European Academy of
Allergy and Clinical Immunology Congress
OSAKA, Japan-Monday 3 June 2019 [ AETOS Wire ]
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”)
today announced new data from an ad-hoc analysis of the Phase 3 HELP
Study™, designed to evaluate the onset of action for TAKHZYRO® (lanadelumab)
during days 0-69 of treatment. The analysis suggests that TAKHZYRO
starts to prevent hereditary angioedema (HAE) attacks during this early
treatment phase, with patients experiencing an 80.1% decrease in mean
monthly attack rate compared to placebo.1 The results were
presented today (PD0369) during the European Academy of Allergy and
Clinical Immunology (EAACI) Congress in Lisbon, Portugal. HAE is a rare,
genetic and potentially life-threatening disorder that can result in
recurrent attacks of oedema (swelling) in various parts of the body.2,3
“The
unpredictable nature of HAE attacks makes living with the disease
physically and emotionally challenging for patients,” said Professor
Marcus Maurer, M.D., Department of Dermatology and Allergy,
Allergie-Centrum-Charité, Charité–Universitätsmedizin Berlin, Germany.
“HAE requires an individualised approach to treatment, and it is
important that a patient’s treatment plan helps reduce the frequency of
attacks. These results are exciting as they suggest that lanadelumab
begins to prevent HAE attacks during the initial phase of treatment.”
The
ad-hoc analysis evaluated the efficacy of TAKHZYRO compared with
placebo during days 0-69 of treatment using the same approach that was
used to evaluate the primary and secondary endpoints during the complete
study period (days 0-182).1 Results from the analysis showed
that in patients receiving the recommended starting dose of TAKHZYRO
300 mg every two weeks, there was a significant reduction in mean
monthly attack rate (80.1% decrease) compared to placebo (Adjusted
P<0 .001="" sup="">1
“Original
data from the HELP Study showed that TAKHZYRO was effective in
preventing HAE attacks over the entire duration of the study and,
according to an exploratory analysis, many patients remained attack-free
during the 16-week steady state period,” said Donatello Crocetta, M.D.,
Franchise Global Medical Unit Head, Rare Immunology and HAE at Takeda.
“This new analysis supports previous study findings and builds on our
understanding of how quickly TAKHZYRO can begin to help prevent HAE
attacks, further supporting its use for appropriate patients as a
preventive therapy that can be administered subcutaneously and begins to
work rapidly.”
Across
all TAKHZYRO treatment arms, (300 mg every two weeks, 300 mg every four
weeks, 150 mg every four weeks), there was an improvement in mean
monthly attack rate, monthly rate of moderate to severe attacks, monthly
rate of attacks requiring acute treatment and the number of attack-free
days, versus placebo, during the entire study period.1
The
most commonly observed adverse reactions (52.4%) associated with
TAKHZYRO were injection site reactions. Of these, 97% were of mild
intensity. Hypersensitivity reaction (mild and moderate pruritus,
discomfort and tingling of tongue) was observed (1.2%).4
TAKHZYRO
300 mg is approved in the European Union and Australia for the routine
prevention of recurrent attacks of HAE in patients aged 12 years and
older. TAKHZYRO 300 mg is approved as prophylaxis to prevent attacks of
HAE in patients aged 12 years and older in the United States and for the
routine prevention of attacks in patients aged 12 years and older in
Canada.
The HELP Study™
The HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ was a multicentre, randomised, double-blind, placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered TAKHZYRO vs. placebo over 26 weeks in 125 patients 12 years of age or older with HAE.4
The HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ was a multicentre, randomised, double-blind, placebo-controlled parallel group trial that evaluated the efficacy and safety of subcutaneously administered TAKHZYRO vs. placebo over 26 weeks in 125 patients 12 years of age or older with HAE.4
The
primary endpoint of the HELP Study™ was the number of
investigator-confirmed HAE attacks over the entire 26-week study
duration. TAKHZYRO demonstrated that subcutaneous injections every two
or four weeks reduced the mean monthly number of attacks across all
three TAKHZYRO treatment arms studies: 300 mg every two weeks, 300 mg
every four weeks and 150 mg of TAKHZYRO every four weeks. At 300 mg
every two weeks, TAKHZYRO reduced the number of mean monthly HAE attacks
by 87% vs. placebo (Adjusted P<0 .001="" sup="">4
Secondary
endpoints included: 1) number of attacks requiring acute treatment and
2) number of attacks assessed as moderate or severe. Overall, each
TAKHZYRO treatment arm demonstrated statistically significant attack
rate reductions compared with placebo for all secondary efficacy
endpoints (Adjusted P<0 .001="" 83="" 87="" acute="" all="" and="" attacks="" comparisons="" for="" including:="" moderate="" or="" requiring="" severe="" sup="" to="" treatment="">4
Complete results from the Phase 3 HELP Study™ were published in the Journal of the American Medical Association (JAMA) on 27 November 2018.5
About Hereditary Angioedema
HAE is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The swelling can be debilitating and painful.2,3,6 Attacks that obstruct the airways can cause asphyxiation and are potentially life-threatening.3,6HAE affects an estimated 1 in 10,000 to 1 in 50,000 people worldwide. It is often under-recognised, under-diagnosed and under-treated.2,7
HAE is a rare genetic disorder that results in recurring attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat. The swelling can be debilitating and painful.2,3,6 Attacks that obstruct the airways can cause asphyxiation and are potentially life-threatening.3,6HAE affects an estimated 1 in 10,000 to 1 in 50,000 people worldwide. It is often under-recognised, under-diagnosed and under-treated.2,7
About TAKHZYRO® (lanadelumab)
TAKHZYRO (lanadelumab) is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.4
TAKHZYRO (lanadelumab) is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.4
TAKHZYRO
is formulated for subcutaneous administration and has a half-life of
approximately two weeks in patients with HAE. TAKHZYRO is intended for
the self-administration or administration by a caregiver, only after
training by a healthcare professional.4
TAKHZYRO Safety Information for Europe
Please consult the TAKHZYRO Summary Product Characteristics (SmPC) before prescribing.
Please consult the TAKHZYRO Summary Product Characteristics (SmPC) before prescribing.
TAKHZYRO
treatment should be initiated under the supervision of a physician
experienced in the management of patients with hereditary angioedema
(HAE). TAKHZYRO may be self-administered or administered by a caregiver
only after training on SC injection technique by a healthcare
professional.
Contraindication
Hypersensitivity to the active substance or to any of the excipients.
Hypersensitivity to the active substance or to any of the excipients.
Warnings and Precautions
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity
reactions have been observed. In case of a severe hypersensitivity
reaction, administration of TAKHZYRO must be stopped immediately and
appropriate treatment must be initiated.
General:
TAKHZYRO is not intended for treatment of acute HAE attacks. In case of
a breakthrough HAE attack, individualized treatment should be initiated
with an approved rescue medication. There are no available clinical
data on the use of lanadelumab in HAE patients with normal C1-INH
activity.
Interference
with coagulation test: Lanadelumab can increase activated partial
thromboplastin time (aPTT) due to an interaction of lanadelumab with the
aPTT assay. The reagents used in the aPTT laboratory test initiate
intrinsic coagulation through the activation of plasma kallikrein in the
contact system. Inhibition of plasma kallikrein by lanadelumab can
increase aPTT in this assay. None of the increases in aPTT in patients
treated with TAKHZYRO were associated with abnormal bleeding adverse
events. There were no differences in international normalised ratio
(INR) between treatment groups.
Sodium
content: This medicinal product contains less than 1 mmol sodium (23
mg) per vial, that is to say essentially 'sodium-free'.
Interactions
No dedicated drug-drug interaction studies have been conducted. Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected.
No dedicated drug-drug interaction studies have been conducted. Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected.
As
expected, concomitant use of the rescue medication C1 esterase
inhibitor results in an additive effect on lanadelumab-cHMWK response
based on the mechanism of action (MOA) of lanadelumab and C1 esterase
inhibitor.
Immunogenicity
Treatment with lanadelumab has been associated with development of treatment emergent anti-drug antibodies (ADA) in 11.9% (10/84) of subjects. All antibody titres were low. The ADA response was transient in 20% (2/10) of ADA positive subjects. 2.4% (2/84) of lanadelumab-treated subjects tested positive for neutralizing antibodies.
Treatment with lanadelumab has been associated with development of treatment emergent anti-drug antibodies (ADA) in 11.9% (10/84) of subjects. All antibody titres were low. The ADA response was transient in 20% (2/10) of ADA positive subjects. 2.4% (2/84) of lanadelumab-treated subjects tested positive for neutralizing antibodies.
The
development of ADA including neutralising antibodies against TAKHZYRO
did not appear to adversely affect the pharmacokinetic (PK) and
pharmacodynamics (PD) profiles or clinical response.
Adverse Reactions
The most commonly observed adverse reaction (52.4%) associated with TAKHZYRO was injection site reactions (ISR) including injection site pain, injection site erythema and injection site bruising. Of these ISRs, 97% were of mild intensity, 90% resolved within 1 day after onset with a median duration of 6 minutes.
The most commonly observed adverse reaction (52.4%) associated with TAKHZYRO was injection site reactions (ISR) including injection site pain, injection site erythema and injection site bruising. Of these ISRs, 97% were of mild intensity, 90% resolved within 1 day after onset with a median duration of 6 minutes.
Hypersensitivity reaction (mild and moderate pruritus, discomfort and tingling of tongue) was observed (1.2%)
|
|
|
|
|
|
Very common (frequency ≥1/10):
|
|
|
Injection site reactions*
|
|
Common (≥1/100 to <1 span="">
|
|
|
Hypersensitivity**, dizziness, rash maclo-papular, myalgia, alanine
aminotransferase increased, aspartate aminotransferase increased. |
*Injection
site reactions include: pain, erythema, bruising, discomfort,
haematoma, haemorrhage, pruritus, swelling, induration, paraesthesia,
reaction, warmth, oedema and rash.
** Hypersensitivity includes: pruritus, discomfort and tingling of tongue.
** Hypersensitivity includes: pruritus, discomfort and tingling of tongue.
For full U.S. Prescribing Information, including the approved indication and important safety information, please visit https://www.shirecontent.com/PI/PDFs/TAKHZYRO_USA_ENG.pdf.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com
1 Riedl,
MA et al. Lanadeluman demonstrates rapid and sustained prevention of
hereditary angioedema attacks: Findings from the HELP study. Poster
Presentation. European Academy of Allergy and Clinical Immunology.
Lisbon, Portugal. June 2019.
2 Cicardi M, Bork K, Caballero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67(2):147-157.
3 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
4 TAKHZYRO® (lanadelumab) Summary of Product Characteristics.
5 Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
6 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
7 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.
2 Cicardi M, Bork K, Caballero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012; 67(2):147-157.
3 Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
4 TAKHZYRO® (lanadelumab) Summary of Product Characteristics.
5 Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121.
6 Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-336.
7 Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations, and treatment. Br J Hosp Med. 2006;67(12):654-657.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005077/en/
Contacts
Media Contacts:
Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095
Media outside Japan
Tsuyoshi Tada
tsuyoshi.tada@takeda.com
+1 (617) 551-2933
